{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:18:51Z","timestamp":1790011131254,"version":"4.0.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shijiazhuang Science and Technology Bureau Foundation","award":["Grant no. 171461553\/151461303"],"award-info":[{"award-number":["Grant no. 171461553\/151461303"]}]},{"name":"Key Research of Medical Science Research of Hebei Province","award":["20170981"],"award-info":[{"award-number":["20170981"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To evaluate the efficacy of double-filtration plasmapheresis (DFPP) treatment of myasthenia gravis (MG) through a systematic review and meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang databases were searched for randomized controlled trials (RCTs) and clinical controlled trials (CCTs) on DFPP for MG from database establishment to June 2019. Two researchers independently screened the articles, extracted the data, and cross checked the results. RevMan 5.3 was used for statistical analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seven RCTs and 2 CCTs were found comprising 329 patients. The results showed that clinical MG remission rate after DFPP treatment was significantly higher (OR\u200a=\u200a4.33; 95% confidence interval [CI], 1.97\u20139.53; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) and the serum levels of antititin antibody was significantly decreased (standardized mean difference [SMD]\u200a=\u200a9.30; 95% CI, 7.51\u201311.08; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). In addition, the quantitative MG (QMG) score, hospital stay and time to remission of MG symptoms, and acetylcholine receptor antibody (AchRAb) decreased in the DFPP treatment group; however, these outcomes had high heterogeneity among the studies. Only one study has reported on the adverse effects, including hypotension and hematoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis suggests that DFPP can be recommended for the short-term mitigation of MG. Because our review was limited by the quantity and quality of the included studies, the above conclusions should be verified by additional high-quality studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025622","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T03:07:39Z","timestamp":1619579259000},"page":"e25622","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis"],"prefix":"10.1097","volume":"100","author":[{"given":"Chaoying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-3219","authenticated-orcid":false,"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250524","first-page":"2555","article-title":"Detection of multiple antibodies in myasthenia gravis and its clinical significance","volume":"123","author":"Wang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Autoimmun Rev"},{"key":"R4-20250524","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R5-20250524","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/039139889802100402","article-title":"Plasma exchange in myasthenia gravis","volume":"21","author":"Kuks","year":"1998","journal-title":"Int J Artif Organs"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol"},{"key":"R8-20250524","first-page":"01","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipourfaz","year":"2016","journal-title":"Acta Neurologica Belgica"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol"},{"key":"R10-20250524","first-page":"406","article-title":"Double filtration plasmapheresis","volume":"26","author":"Agishi","year":"1980","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"R11-20250524","first-page":"318","article-title":"Efficiency and biocompatibility of a new immunosorbent","volume":"28","author":"Yamazaki","year":"1982","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<177::AID-JCA4>3.0.CO;2-L","article-title":"Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis","volume":"14","author":"Yeh","year":"1999","journal-title":"J Clin Apher"},{"key":"R13-20250524","article-title":"Chapter 8: assessing risk of bias in included studies","author":"Higgins","year":"2011","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 [Updated March 2011]"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1744-9987.1997.tb00052.x","article-title":"Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis","volume":"1","author":"Okada","year":"1997","journal-title":"Ther Apher"},{"key":"R15-20250524","first-page":"40","article-title":"Clinical observation of 26 cases of myasthenia gravis treated by DFPP combined with methylprednisolone","volume":"45","author":"Gong","year":"2005","journal-title":"Shandong Med J"},{"key":"R16-20250524","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jocn.2013.11.046","article-title":"Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action","volume":"21","author":"Zhang","year":"2014","journal-title":"J Clin Neurosci"},{"key":"R17-20250524","first-page":"1228","article-title":"Double filtration plasmapheresis combined with glucocorticoid treatment for myasthenia gravis: symptom remission and variation of immune antibodies","volume":"19","author":"Han","year":"2015","journal-title":"Chin J Tissue Eng Res"},{"key":"R18-20250524","first-page":"07","article-title":"Clinical study of ia in the treatment of generalized myasthenia gravis","volume":"29","author":"Zang","year":"2015","journal-title":"China Foreign Med Treat"},{"key":"R19-20250524","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1468-1331.2011.03424.x","article-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","volume":"18","author":"Chien","year":"2011","journal-title":"Eur J Neurol"},{"key":"R20-20250524","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with mg","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol"},{"key":"R21-20250524","first-page":"87","article-title":"A clinical absolute and relative score system for myasthenia gravis","volume":"30","author":"Xiuyun","year":"1997","journal-title":"Chin J Neurol"},{"key":"R22-20250524","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"R23-20250524","first-page":"1413","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"key":"R24-20250524","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3109\/08916930903518099","article-title":"Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis","volume":"43","author":"Lagoumintzis","year":"2010","journal-title":"Autoimmunity"},{"key":"R25-20250524","first-page":"737","article-title":"Intravenous immunoglobulin therapy in neurological disease","volume":"59","author":"Cojocaru","year":"2011","journal-title":"Farmacia"},{"key":"R26-20250524","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM199208063270610","article-title":"The risk of transfusion-transmitted infection","volume":"327","author":"Dodd","year":"1992","journal-title":"N Engl J Med"},{"key":"R27-20250524","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jca.1026","article-title":"Coagulation abnormalities in serial double-filtration plasmapheresis","volume":"16","author":"Yeh","year":"2010","journal-title":"J Clin Apher"},{"key":"R28-20250524","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"13","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R29-20250524","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0404.1999.tb00401.x","article-title":"Double filtration plasmapheresis in myasthenia gravis - analysis of clinical efficacy and prognostic parameters","volume":"100","author":"Yeh","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"R30-20250524","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0404.2003.00107.x","article-title":"Predicting the course of myasthenic weakness following double filtration plasmapheresis","volume":"108","author":"Yeh","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"R31-20250524","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1525-1594.2012.01531.x","article-title":"A decrease in the percentage of cd3+ cells is correlated with clinical improvement during plasmapheresis in patients with myasthenia gravis","volume":"37","author":"Chien","year":"2013","journal-title":"Artif Organs"},{"key":"R32-20250524","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"R33-20250524","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.2005.00374.x","article-title":"Myasthenia gravis: clinical, immunological, and therapeutic advances","volume":"111","author":"Romi","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"R34-20250524","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1196\/annals.1254.055","article-title":"Myasthenia gravis in individuals over 40","volume":"998","author":"Aarli","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R35-20250524","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"R36-20250524","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","article-title":"Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations","volume":"111","author":"Romi","year":"2000","journal-title":"J Neuroimmunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T17:10:44Z","timestamp":1748106644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025622"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":36,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025622","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"2020-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}